[HTML][HTML] Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study
Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech… - New England journal …, 2017 - Mass Medical Soc
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study
KK Ray, N Dhalwani, M Sibartie… - … Journal-Quality of …, 2022 - academic.oup.com
Aims To describe the characteristics of patients receiving evolocumab in clinical practice
across 12 European countries and simulate the association between low-density lipoprotein …
across 12 European countries and simulate the association between low-density lipoprotein …
[HTML][HTML] Effectiveness, adherence, and safety of evolocumab in a Swiss multicenter prospective observational study
D Nanchen, D Carballo, S Bilz, H Rickli… - Advances in …, 2022 - Springer
Introduction The aims of this study were to describe patient characteristics, lipid parameters,
lipid-lowering drug use, and safety of patients receiving evolocumab in a real-world clinical …
lipid-lowering drug use, and safety of patients receiving evolocumab in a real-world clinical …
[HTML][HTML] Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results …
K Al Faraidy, M Akbar, M Shehri, M Aljarallah… - PLoS …, 2023 - journals.plos.org
Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality
across the world, including in the Arabian Gulf. The present study aimed to describe the …
across the world, including in the Arabian Gulf. The present study aimed to describe the …
Evolocumab: considerations for the management of hyperlipidemia
BS Wiggins, J Senfield, H Kassahun, A Lira… - Current Atherosclerosis …, 2018 - Springer
Abstract Purpose of Review To review the efficacy, safety, pharmacology, and
pharmacokinetics of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) …
pharmacokinetics of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) …
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott… - … England Journal of …, 2015 - Mass Medical Soc
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data
A Qamar, RP Giugliano, AC Keech, JF Kuder… - JAMA …, 2019 - jamanetwork.com
Importance Little is known about the heterogeneity in low-density lipoprotein cholesterol
levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor …
levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor …
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …